Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, May 30, 2023
[ Tue, May 30th 2023
] - WOPRAI
[ Tue, May 30th 2023
] - WOPRAI
[ Tue, May 30th 2023
] - WOPRAI
[ Tue, May 30th 2023
] - WOPRAI
[ Tue, May 30th 2023
] - WOPRAI
[ Tue, May 30th 2023
] - WOPRAI
[ Tue, May 30th 2023
] - WOPRAI
[ Tue, May 30th 2023
] - WOPRAI
[ Tue, May 30th 2023
] - WOPRAI
[ Tue, May 30th 2023
] - WOPRAI
[ Tue, May 30th 2023
] - WOPRAI
[ Tue, May 30th 2023
] - WOPRAI
[ Tue, May 30th 2023
] - WOPRAI
[ Tue, May 30th 2023
] - WOPRAI
[ Tue, May 30th 2023
] - WOPRAI
[ Tue, May 30th 2023
] - WOPRAI
[ Tue, May 30th 2023
] - WOPRAI
[ Tue, May 30th 2023
] - WOPRAI
[ Tue, May 30th 2023
] - WOPRAI
[ Tue, May 30th 2023
] - WOPRAI
[ Tue, May 30th 2023
] - WOPRAI
[ Tue, May 30th 2023
] - WOPRAI
[ Tue, May 30th 2023
] - WOPRAI
[ Tue, May 30th 2023
] - WOPRAI
[ Tue, May 30th 2023
] - WOPRAI
[ Tue, May 30th 2023
] - WOPRAI
[ Tue, May 30th 2023
] - WOPRAI
[ Tue, May 30th 2023
] - WOPRAI
Raghuram Selvaraju Reiterated (BTAI) at Strong Buy and Held Target at $66 on, May 30th, 2023
Raghuram Selvaraju of HC Wainwright & Co., Reiterated "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy and Held Target at $66 on, May 30th, 2023.
Raghuram has made no other calls on BTAI in the last 4 months.
There are 4 other peers that have a rating on BTAI. Out of the 4 peers that are also analyzing BTAI, 2 agree with Raghuram's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Corinne Jenkins of "Goldman Sachs" Maintained at Hold with Decreased Target to $25 on, Friday, May 26th, 2023
- Chris Howerton of "Jefferies" Downgraded from Strong Buy to Hold and Increased Target to $22 on, Friday, March 10th, 2023
These are the ratings of the 2 analyists that currently disagree with Raghuram
- Graig Suvannavejh of "Mizuho" Maintained at Strong Buy with Increased Target to $40 on, Wednesday, May 10th, 2023
- Yatin Suneja of "Guggenheim" Maintained at Strong Buy with Decreased Target to $46 on, Tuesday, May 9th, 2023
